A Phase Ib/II, Open-Label, Multi-Center Study of EMB-01 in Combination With Osimertinib in Patients With Advanced/Metastatic EGFR Mutant Lung Cancer
This study is testing a combination of two targeted cancer drugs, EMB-01 and osimertinib, for patients with advanced lung cancer. Researchers want to find the best dose and check for side effects to see if this combination works better than standard treatments.
You may be able to join if you are 18 or older and have advanced lung cancer with a specific EGFR gene mutation that has continued to grow after previous treatments. You must also be well enough to follow study rules and provide blood samples for testing.
Participants will receive a combination of the study drug EMB-01 and the medication osimertinib to help block cancer cell growth. Doctors will closely monitor your health, review your imaging scans, and check for any side effects throughout the study.
The study takes place at multiple medical centers, including locations in California and Massachusetts in the United States, as well as in China. The current status of the study is not specified, so you will need to contact the study team to confirm if they are actively enrolling.
- 1Tests a new drug combination to treat advanced lung cancer with EGFR mutations.
- 2Combines the investigational drug EMB-01 with the targeted therapy osimertinib.
- 3Requires regular check-ups, imaging scans, and blood samples to monitor your safety and progress.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.